Assessment of IORT application in early stage breast cancer surgery: a cross-sectional study
Text Complet
Compartir
Breast conserving therapy has been proved to be equivalent to mastectomy-
based treatment and nowadays is the standard of care approach for patients
with early-stage breast cancer. Adjuvant radiotherapy has demonstrated to
improve local control after breast conserving surgery is performed. Since
most local recurrences appear at or near the localization of the primary
tumour, accelerated partial-breast irradiation (APBI) techniques have been
developed. This form of radiation allows to target smaller breast tissue.
Intraoperative radiotherapy (IORT) is a form of APBI that enables to deliver a
single dose of irradiation to the tumour bed during the surgical frame time,
which shortens the treatment time and improves the quality of life of the
patients. This procedure was supported by two randomized trials and today
IORT is an established alternative to traditional whole breast radiotherapy
(WBRT) for selected patients. Based on the evidence regarding IORT, in 2019
a clinical protocol for the application of this modality of radiotherapy was
introduced in Hospital Universitari Josep Trueta (HUJT) in Girona. The
patients who meet its eligibility criteria undergo breast conserving surgery
plus IORT. However, some patients still require additional external beam
radiotherapy (EBRT) due to adverse outcomes in the final pathological
assessment.
Objective: The aim of this study is to perform an assessment of the current Protocol for
IORT application of HUJT. Our objective is to identify possible eligibility
criteria that may be adjusted with the intend to reduce the number of
patients who require additional EBRT after the initial IORT treatment.
Participants: Women diagnosed with early-stage breast cancer who underwent breast
conserving surgery plus IORT in HUJT.
Methods: A cross-sectional design carried out in the Breast Pathology Unit of HUJT, a
tertiary referral hospital in Girona. The study will be carried out from 2020 to
2022. Data on tumour features, pathological outcomes and patient
characteristics will be collected and ascertained
Aquest document està subjecte a una llicència Creative Commons:Reconeixement - No comercial - Sense obra derivada (by-nc-nd)
![Creative Commons by-nc-nd4.0](/themes/BiblioUdG/images/creative-commons-by-nc-nd.png)
Localització
Ítems relacionats
Mostrant ítems relacionats per títol, autor o matèria